Skip to content
Open in App
Achieve Life Sciences logo

Achieve Life Sciences

web2

Achieve Life Sciences is a clinical stage pharmaceutical company developing cytisinicline as a...

Symbol · ACHV
Company profile

About

Achieve Life Sciences is a clinical stage pharmaceutical company developing cytisinicline as a potential prescription treatment to help people stop smoking and overcome nicotine dependence. Cytisinicline acts on nicotine receptors involved in withdrawal symptoms and the reinforcing effects of tobacco use. The company has conducted late stage clinical trials evaluating smoking cessation and has also investigated the treatment's potential for people seeking to stop using electronic cigarettes. Its development activities include clinical research, regulatory preparation, and planning for potential commercialization. Cytisinicline remains an investigational treatment in the United States, and commercial availability depends on regulatory approval.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ACHV
Expert coverage

1 expert evaluated Achieve Life Sciences.

Orbitrum research

Experts evaluating Achieve Life Sciences

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment